Trazodone, Serum
Trazodone is a member of the class of drugs known as antidepressants. The use of antidepressants is one of the primary ways to treat clinical depression. Other clinical uses of antidepressants are for disorders or clinical conditions such as obsessive-compulsive disorders, chronic pain, eating disorders, anxiety or panic disorders, peptic ulcer disease or childhood enuresis. Trazodone is a member of the second generation of antidepressants.
Trazodone is metabolized to meta-Chlorophenylpiperazine, which is also biologically active. The half-lives of antidepressant drugs are quite variable. The half-life of Trazodone is between 7-10 hours. Many of the therapeutic ranges for antidepressant drugs have not been established or there is non-consensus.
The effects associated with trazodone abuse include sleepiness, headache, xerostomia, tachycardia, seizures, nausea, vomiting, tremors, and coma when taken to excess.
Trazodone is one of the most frequently encountered drugs of abuse due to the large majority of the population that is taking them, the frequency with which these drugs are prescribed, and their high potential for serious side effects.
- Therapeutic monitoring
- Drug abuse evaluation
- Toxicity assessment
- Patient Compliance
Therapeutic concentrations in blood: 650-1500 ng/mL
Toxic concentrations: > 4000 ng/mL
Fatal concentrations: variable
Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.
Cut-Off Ranges
Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection, whether it is a qualitative method such as IA, or a quantitative method such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.
Serum (SST).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Antidepressant DEA Drug Fact Sheet.
- Levine, Barry (Ed). Therapeutic Drugs II: Antidepressants. In: Principles of Forensic Toxicology, 4th Ed. Washington DC: AACC Press; 2013: 403-420.
- Balant-Georgia AE, Balant LP. Milestones in clinical pharmacology. Therapeutic drug monitoring of antidepressants. Clin Ther. 1992;14(4):612-4.
- Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
- Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
- Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7):169-79.
- Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman and Gilman’s the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill Co.; 1996
- Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4):7-20.
- Zherdev VP, Caccia S, Garattini S, Ekonomov AL. Species differences in phenazepam kinetics and metabolism. Euro J Drug Metab Pharm. 1982;7:191-6.